Bone mineral density and bone metabolism in postmenopausal women with type 2 diabetes in a Chinese community: a cross-sectional study

Wu Han  
Nanjing Medical University  https://orcid.org/0000-0002-8235-3971

Yufan Zhang  
Nanjing Medical University

Wenbin Zhou  
Nanjing Medical University

Guolong Zhang  
Danyang Lianhu Community Service Center in Jiangsu

Jindi Wang  
Danyang Lianhu Community Service Center in Jiangsu

Jingjing Xu  
Nanjing Medical University

Tao Yao  
Nanjing Medical University

Jing Dai  
Nanjing Medical University

Wei He  (✉ hewei1007@126.com)  
https://orcid.org/0000-0002-3503-8530

---

Research article

**Keywords:** type 2 diabetes mellitus, Bone mineral density, Bone turnover markers, Osteoporosis fracture

**Posted Date:** November 23rd, 2020

**DOI:** https://doi.org/10.21203/rs.2.21731/v2

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: There is growing evidence of a complex interaction between type 2 diabetes (T2DM) and osteoporosis. The purpose of this study was to further study the relationship between Bone turnover markers (BTMs) and fasting blood glucose (FBG) in postmenopausal patients with type 2 diabetes and to analyze the effect of hyperglycemia on bone metabolism.

Methods: Six hundred and twelve (612) postmenopausal women were included, including one hundred and seven (107) subjects with T2DM and five hundred and five (505) subjects without diabetes. Bone mineral density (BMD) was measured by DXA (dual-energy X-ray absorptiometry). Markers of bone formation Type 1 collagen N-terminal peptide (P1NP) and resorption C-telopeptide of type I collagen (CTX) were quantified.

Results: Compared to controls, postmenopausal women with diabetes had a higher prevalence of previous osteoporosis fracture (27.1% vs. 17.4% for diabetic and nondiabetic women, respectively) and a higher BMD. The P1NP level in women with T2DM was 49.451 ng/ml, while in N-DM individuals, it was 58.633 ng/ml, (p = 0.017). The CTX level in women with T2DM was 0.325 ng/ml, while in N-DM individuals, it was 0.412 ng/ml (p=0.039). In addition, P1NP was significantly negatively associated with age (β=-0.590; p= 0.002) and FBG (β=-1.950; p = 0.035). CTX was negatively associated with FBG (β=-0.029; p = 0.015).

Conclusions: T2DM was associated with higher BMD and paradoxically, with an increased risk of fracture. Postmenopausal women with T2DM had lower bone turnover than controls. With increased levels of FBG, bone formation and bone resorption were reduced, and the overall bone turnover level was reduced.

Background

As the population ages, the incidence of osteoporosis and diabetes is increasing. Observational studies in recent years have analyzed several aspects of the association between diabetes and osteoporosis with conflicting results.

Bone mineral density (BMD) is the most commonly used measurement in the assessment of osteoporosis status and risk for osteoporosis fracture in the elderly population. The diagnostic criteria for osteoporosis are based on BMD, and thus far, there is less information on the BMD of patients with type 2 diabetes. BMD significantly decreases in type 1 diabetes mellitus (T1DM)[1-4]; however, in type 2 diabetes mellitus (T2DM), the results are controversial. Early studies suggested that BMD in T2DM patients was lower than, equal to, or higher than that of the control groups[5-8]. Interestingly, studies in recent years have shown that these subjects have significantly higher BMD than nondiabetic people. It is well-known that individuals with T2DM have a higher risk of fracture of the hip, spine, and peripheral sites than nondiabetic individuals[9-12].
Patients with T2DM have multiple chronic complications, such as retinopathy, kidney disease, neuropathy, coronary heart disease, stroke and dementia. Bone is also one of the organs that is affected by T2DM. It is estimated that patients with T2DM have a 1.7-fold increased risk of fracture compared with nondiabetics[13]. Recent studies [14, 15] suggest a complicated relationship between bone metabolism and glucose metabolism. Osteoporosis fracture is considered to be one of the complications of DM, and is called diabetic osteopathy, or “diabetic osteoporosis(DOP)”. The Fracture Risk Assessment Tool (FRAX) model and BMD underestimate major osteoporotic and hip fracture risks. Bone turnover markers (BTMs) may be a useful exploratory method[16]. BMD is mainly determined by the mineral composition in the bone, but cannot reflect the changes of organic components such as type I collagen in the bones and the changes in bone metabolism in the short term. The BTMs can not only sensitively reflect the dynamic changes of bone metabolism, but also can be used to monitor the efficacy of anti-OP drugs. BTMs are chemical compounds, a set of proteins and their derivatives, released during bone remodeling by osteoblasts or osteoclasts[17]. Type 1 collagen N-terminal peptide (P1NP) is a specific marker reflecting the activity of osteoblasts. BTMs can reflect the activity of osteoclast cells, such as C-telopeptide of type I collagen (CTX), N-telopeptide of type I collagen (NTX), tartrate-resistant acid phosphatase (TRAP), and deoxypyridinoline[18]. PINP and CTX are recommended as bone markers by the International Osteoporosis Foundation (IOF) and are widely used in clinical practice.

The current study aimed to identify the relationship between bone turnover markers and fasting blood glucose (FBG) in postmenopausal patients with type 2 diabetes in a Chinese population. The effect of hyperglycemia on bone metabolism was also determined.

**Methods**

**Subjects and Methods**

We performed a cross-sectional study, enrolling 1000 postmenopausal women aged 45–74 years from January to December 2017 from Danyang Lianhu Community Service Center in Jiangsu. All T2DM individuals had been diagnosed according to the 2010 criteria of the American Diabetes Association (ADA) and the 1999 World Health Organization definition. We excluded individuals with diseases and those who were taking medicine known to affect BMD and bone metabolism, i.e., subjects who had hepatic, gastrointestinal, kidney, thyroid or malignant disorders causing low BMD and subjects who had been treated with hormone therapy, calcium supplements, vitamin D, bisphosphonates, antipsychotic drugs, diuretics or thiazolidinediones. Finally, a total of 612 participants (107 subjects with T2DM and 505 subjects without diabetes) were retained for further analysis.

Baseline data were recorded during a face-to-face interview by a trained professional using a structured questionnaire, which included questions about age, medical history, menopause age, physical activity, related treatment and family history. The participants were accurately measured for height, weight, and blood pressure.

**BMD by DXA**
DXA (dual-energy X-ray absorptiometry) was performed on all participants on the lumbar spine (L1–L4) and femoral regions (femoral neck and total hip) with Hologicequipment (Danyang Lianhu Community Service Center; variation coefficient<1%). According to the World Health Organization (WHO) 1994 osteoporosis diagnostic criteria, in postmenopausal women, normal BMD is indicated by a T score ≥-1.0; osteopenia is indicated by -2.5≤T score≤-1.0); and osteoporosis is indicated by a T score ≤ -2.5.

**Biochemical parameters**

In the morning, after approximately eight hours of fasting, blood samples from each participant were collected for total cholesterol, high-density lipoprotein and low-density lipoprotein cholesterol, triglycerides, fasting blood glucose, P1NP and CTX. Blood samples for fasting blood glucose were centrifuged at 1500 g for 10 minutes at room temperature and analyzed on the same day. Plasma glucose concentrations were measured by an Olympus AU2700 analyzer using the manufacturer's kits. The bone formation marker P1NP and the bone resorption marker CTX were determined by electrochemiluminescence immunoassay (Roche).

**Osteoporosis fracture ascertainment**

In this study, the diagnostic criteria for osteoporosis fractures were residents’ self-reported history of fragility fractures or resident-reported imaging fractures. A fragility fracture is defined as a fracture that results from a fall to the ground or a similar degree of trauma from a standing position or lower than a standing position[19].

**Ethical aspects**

The study was approved by Danyang People's Government and Danyang Lianhu Community Service Center in Jiangsu. All participants provided written informed consent.

**Statistical analyses**

Baseline data were input into the computer with Epidata3.1. All statistical analyses were performed with IBM-SPSS version 24.0 for Windows (SPSS, Chicago, Illinois), based on the above two groups. Descriptive statistics, including means, frequencies, and percentages, were used to describe the study population and look at differences between groups. Continuous data were expressed as the mean and standard deviation (mean ± SD). The comparison of the means of the two groups was performed by independent sample t test. The categorical variables were analyzed by chi-squared test, and the regression analysis was performed by multiple linear regression after adjustment for age, menopause age, weight and BMI. P-values<0.05 were considered statistically significant.

**Results**

**Basic characteristics of the participants**
The clinical characteristics of the enrolled subjects are summarized in Table 1. All subjects included in this study were postmenopausal women. There were no statistically significant differences in age, menopause age, diastolic pressure, height, total cholesterol, LDL cholesterol and weekly moderate physical activity between the two groups (p>0.05). However, the patients with T2DM had significantly higher systolic pressure, weight, body mass index, fasting blood glucose and triglycerides, and lower HDL cholesterol levels than the controls (p<0.05). 75 of 107 patients received Oral anti-diabetic agents treatment, 18 patients used Insulin only, and 14 patients were using combination therapy. In the study, diabetic patients were more likely than nondiabetic patients to have complications with hypertension (57.9% vs. 40.6%, respectively, p=0.001) and cerebral apoplexy (5.9% vs. 1.0%, respectively, p=0.001). There was also no statistically significant difference in family history of fractures. However, postmenopausal women with diabetes had a higher prevalence of previous osteoporosis fracture than those without diabetes (27.1% vs. 17.4%, P=0.021).

**Table 1**

Basic characteristics of the participants

| Characteristics               | T2DM          | N-DM          | p-Value |
|------------------------------|---------------|---------------|---------|
| Number                       | 107           | 505           | ...     |
| Age (years)                  | 66.81±9.05    | 66.78±7.36    | 0.970   |
| Menopause age (years)        | 49.24±3.69    | 49.50±3.73    | 0.516   |
| Systolic pressure (mmHg)     | 138.27±20.04  | 133.15±16.77  | 0.006   |
| Diastolic pressure (mmHg)    | 85.00±9.97    | 83.83±9.06    | 0.234   |
| Height (cm)                  | 155.45±5.25   | 155.15±5.79   | 0.617   |
| Weight (kg)                  | 62.29±10.06   | 59.09±8.78    | 0.001   |
| BMI (kg/m2)                  | 25.74±3.72    | 24.55±3.41    | 0.001   |
| FBG (mmol/L)                 | 7.92±2.02     | 5.23±0.58     | 0.000   |
| TC (mmol/L)                  | 5.16±1.05     | 6.51±2.82     | 0.621   |
| TG (mmol/L)                  | 2.40±1.59     | 1.88±1.24     | 0.000   |
| LDL (mmol/L)                 | 2.74±0.90     | 3.45±13.88    | 0.594   |
| HDL (mmol/L)                 | 1.37±0.51     | 1.48±0.48     | 0.029   |
| Moderate activity≥1h per week| 6378.9%       | 3978.8%       | 0.233   |
| Oral anti-diabetic agents    | 7570.1%       | None          | NA      |
| Insulin                      | 1816.8%       | None          | NA      |
| Insulin+Oral anti-diabetic agents | 1413.1%       | None          | NA      |
| Hypertension                 | 62 (57.9%)    | 205 (40.6%)   | 0.001   |
| Hyperlipidemia               | 12 (11.2%)    | 43 (8.5%)     | 0.375   |
| Cerebral apoplexy            | 6 (5.9%)      | 5 (1.0%)      | 0.001   |
| Coronary heart disease       | 9 (8.4%)      | 25 (4.9%)     | 0.156   |
| Family history of fractures  | 6 (5.6%)      | 14 (2.8%)     | 0.134   |
| Osteoporosis fracture        | 29 (27.1%)    | 88 (17.4%)    | 0.021   |
| Wrist                        | 9             | 21            |
| Hip                          | 8             | 33            |
| Others bone                  | 12            | 34            |

Continuous variables are expressed as the mean ± SD, and categorical variables are expressed as n (%)

BMI body mass index, FBG fasting blood glucose, TC total cholesterol, TG triglycerides, LDL LDL cholesterol, HDL HDL cholesterol

The postmenopausal women with T2DM had higher BMD (in the femoral regions) than the N-DM controls.

As shown in Table 2, the lumbar spine BMD was not significantly different between groups (T2DM 0.708 ± 0.47 g/cm² vs. Nondiabetes 0.666± 0.43 g/cm², P = 0.373). There were differences in the femoral neck
and total hip (Femoral neck: T2DM 0.830 ± 0.14 g/cm2 vs. Nondiabetes 0.764±0.12 g/cm2, P=0.000; Total hip: T2DM 0.882 ± 0.14 g/cm2 vs. Nondiabetes 0.817±0.13 g/cm2, P=0.000). The T-scores of all regions were significantly higher in the T2DM group than in the nondiabetic group (Lumbar spine: p=0.002; Femoral neck: P=0.000; Total hip: P=0.000).

Table 2 BMD and T-scores for T2DM and N-DM subjects

|                | T2DM          | N-DM          | p-Value |
|----------------|---------------|---------------|---------|
| Lumbar spine   | 0.708±0.47    | 0.666±0.43    | 0.373   |
| T-score        | -0.761±1.39   | -1.18±1.26    | 0.002   |
| Femoral neck   | 0.830±0.14    | 0.764±0.12    | 0.000   |
| T-score        | -0.839±1.13   | -1.389±1.02   | 0.000   |
| Total hip      | 0.882±0.14    | 0.817±0.13    | 0.000   |
| T-score        | -0.713±1.07   | -1.221±1.01   | 0.000   |

Data are expressed as the mean ± SD

_BMD_ bone mineral density

Postmenopausal women with T2DM had lower BTMs than N-DM controls.

As shown in Table 3 and Figure 1, the BTMs were lower in subjects with T2DM compared with subjects without diabetes: P1NP levels were significantly lower in T2DM subjects compared to controls (T2DM, 49.451±35.73 ng/ml vs. controls, 58.633±36.21 ng/ml; p=0.017), and CTX levels were also significantly lower in T2DM subjects compared to controls (T2DM, 0.325±0.24 ng/ml vs. controls, 0.412±0.42 ng/ml; p=0.039).

Table 3 Bone turnover biomarkers, P1NP and CTX in T2DM and N-DM subjects

|                | T2DM         | N-DM         | t-Value | p-Value |
|----------------|--------------|--------------|---------|---------|
| P1NP (ng/mL)   | 49.451±35.73 | 58.633±36.21 | -2.388  | 0.017   |
| CTX (ng/mL)    | 0.325±0.24   | 0.412±0.42   | -2.071  | 0.039   |

Data expressed as mean ± SD

_P1NP_ procollagen 1 N-terminal peptide, _CTX_ procollagen 1 C-terminal peptide

Multiple linear regression analysis was used to analyze the data for all subjects to search for possible associations between BTMs and the above biochemical parameters (Table 4). The data showed that P1NP was significantly negatively associated with age (β=-0.590; p= 0.002) and fasting blood glucose (β=-1.950; p = 0.035). CTX was negatively associated with fasting blood glucose (β=-0.029; p = 0.015) but not with age (β=-0.003; p = 0.142).

Table 4 Multiple linear regression analysis for association of P1NP and CTX as dependent variables with age, menopause age and above biochemical parameters
Independent variables  | β     | Std.Error | Standardized Beta | p-Value | 95% Confidence Interval for B  |
|----------------------|-------|-----------|-------------------|---------|-------------------------------|
|                      |       |           |                   |         | Lower Bound | Upper Bound |
| **P1NP**             |       |           |                   |         |               |             |
| Age                  | -0.590| 0.190     | -0.125            | 0.002   | -0.976        | -0.246       |
| FBG                  | -1.950| 1.028     | -0.077            | 0.035   | -3.845        | 0.075        |
| **CTX**              |       |           |                   |         |               |             |
| Age                  | -0.006| 0.013     | -0.118            | 0.062   | -0.012        | -0.002       |
| FBG                  | -0.029| 0.011     | -0.104            | 0.015   | -0.049        | -0.005       |

**Discussion**

To the best of our knowledge, this is a relatively large-sample study in a Chinese community with complete markers of bone metabolism and a large Chinese cross-sectional study that investigates the associations of T2DM and BMD, BTMs, and osteoporosis fracture in postmenopausal women. In our study, we found a negative correlation between FPG and BTMs and speculated that lower levels of P1NP and CTX may be associated with an increased fracture risk in patients with type 2 diabetes. We hypothesized that the underlying mechanism might be that hyperglycemia leads to bone marrow alterations and damaged differentiation potential, which changes bone metabolism, resulting in reduced bone turnover, poor bone quality, and ultimately fractures.

The effect of T2DM on BMD remains controversial, although fracture risk significantly increases in patients with T2DM[20, 21]. Epidemiological surveys show that in patients with type 1 diabetes, BMD is reduced, bone mass decreases and the incidence of osteoporosis ranges from 48% to 72%[22]. BMD is increased, decreased or unchanged for patients with T2DM. These results have been reported in both domestic and foreign literature[23]. In our study, there was a significant increase in BMD in patients with type 2 diabetes, which was consistent with other studies[9, 24]. This further confirms that BMD may be an inappropriate tool for assessing the risk of bone loss and fracture in patients with type 2 diabetes. For patients with diabetes, T value greater than -2.5 may be required as a cut-off value for osteoporosis diagnosis.

Recent studies have shown that osteoporosis fracture is one of the complications of diabetes in the skeletal system, but the specific mechanism is not clear[20, 25]. The higher incidence of fractures in the diabetic population may be associated with specific complications of diabetes, including peripheral neuropathy, impaired visual, postural hypotension, hypoglycemic attacks, and vascular disease. The deficiency of this article is that there is no additional detailed information about the specific types of fracture observed. Therefore, it is difficult to further clarify the causal relationship between diabetes and osteoporosis fractures.

BTMs are considered independent diagnostic and prognostic indicators or as a supplementary index to BMD for osteoporosis fractures. Previous studies of bone turnover markers in diabetes have been limited and controversial, but most scholars have agreed that BTMs might be an important link between bone
metabolism and glucose metabolism. Hussein RM [26]{Hussein, 2017 #133} and showed that patients with T2DM exhibited a significantly lower serum osteocalcin and calcium and a higher alkaline phosphatase compared to the controls. Moreover, osteocalcin was negatively correlated with FBG and DM duration. Wang J analyzed three BTMs in the Chinese population. The levels of N-terminal osteocalcin (N-MID), type 1 collagen N-terminal peptide (PINP) and type 1 collagen carboxyl-terminal peptide (CTX) were significantly decreased in the T2DM groups compared to the controls (P<0.01), revealing that BTMs are highly associated with T2DM, insulin sensitivity and beta cell function, which are compatible with ours. Another study concluded that bone formation was inhibited in postmenopausal women with T2DM, but that inconsistent with our research is that there was no significant difference in bone resorption[27]. Reyes-García R[28] showed lower levels of bone resorption markers and PTH-i compared with the levels of controls. The lower the bone metabolism is, the higher the incidence of fracture.

In our study, women with T2DM showed lower bone turnover compared with N-DM controls. These results also supported the above findings. Multiple regression analysis showed that both PINP and CTX were affected by fasting blood glucose. The higher the levels of FBG were, the lower the levels of PINP and CTX. This finding suggests that postmenopausal T2DM patients with increased FBG have decreased bone formation, bone resorption, and overall bone turnover. In this study, there was a lack of data on the course of diabetes, diabetes treatment plans, blood glucose control, glycosylated hemoglobin and other more accurate data. There are too many factors affecting FBG, which alone may be insufficient.

Advanced glycosylation end products (AGEs), stable cross-linking products, are formed by a series of nonenzymatic reactions between glucose and protein and are significantly increased in individuals with T2DM[29]. AGEs affect attachment to the collagen matrix and interfere with the development of osteoblasts[30, 31]. AGEs may also decrease bone resorption by altering the structural integrity of matrix proteins and inhibiting osteoclastic differentiation[29]. In postmenopausal T2DM patients with increased fasting glucose, both formation and bone resorption were decreased, and the level of overall bone transformation was decreased. RANKL is an agonist that regulates important aspects of osteoclasts, such as differentiation, fusion, survival, activation, and apoptosis[32]. Hyperglycemia has been shown to inhibit the above pathway mediated by RANKL and could induce low bone turnover[33]. Although there is no significant reduction in BMD in patients with T2DM, another factor that may contribute to the increase in fractures is microstructural abnormalities. Increased cortical porosity is a key determinant of bone fragility[34]. In a recent community study, T2DM and elevated fasting glucose levels resulted in unfavorable cortical microarchitecture at the distal tibial cortex[35]. This may indicate that the weakening of bone biomechanics is beyond the range of BMD measurements and that there may be significant microscopic contributors to osteoporosis fracture. Thus, BTMs may be a more sensitive alternative to BMD in assessing fracture risk in patients with diabetes.

Our study has some limitations. First, in our cross-sectional study, we only observed an association between BTMs and glucose metabolism, not a causal relationship. Further forward-looking and biomechanical studies are needed to confirm other potential associations. Second, FBG is only a
temporary phenomenon, and there are too many factors influencing it. We need a more stable long-term indicator, such as glycosylated hemoglobin or glycosylated plasma protein, to further explore the relationship between blood glucose and bone metabolism. Third, a few subjects with diabetes may have T1DM as we could not distinguish between type 1 and type 2 diabetes. Fourth, we lack data on the relationship between BTMs and glucose metabolism in premenopausal women, which may be different from the population included in this study. According to previous data, the level of sex hormone can affect bone metabolism[15]. This means that we truly need to explore this issue further in different populations.

In conclusion, postmenopausal women with T2DM had higher BMD, but the risk of osteoporotic fracture was relatively high, and BMD underestimated the risk. The study suggested that actively controlling blood glucose may help maintain bone turnover balance and improve bone mass, thereby reducing the risk of fracture. The detection of BTMs in patients with type 2 diabetes can predict the risk of diabetes complicated with osteoporosis earlier than BMD, which is convenient for early intervention and treatment.

**Abbreviations**

- **BMD**: Bone mineral density
- **T1DM**: Type 1 diabetes mellitus
- **T2DM**: Type 2 diabetes mellitus
- **P1NP**: Type 1 collagen N-terminal peptide
- **CTX**: C-telopeptide of type I collagen
- **NTX**: N-telopeptide of type I collagen
- **TRAP**: Tartrate-resistant acid phosphatase
- **FBG**: Fasting blood glucose
- **ADA**: American Diabetes Association ADA
- **DXA**: Dual-energy X-ray absorptiometry
- **AGEs**: Advanced glycosylation end products

**Declarations**

All the authors of article, including Han Wu, Yufan Zhang, Wenbin Zhou, Guolong Zhang, Jindi Wang, Jingjing Xu, Tao Yang, Jing Dai, Wei He declare that they have no conflicts of interest.


**Ethics approval and consent to participate**

The study was approved by Danyang People's Government and Danyang Lianhu Community Service Center in Jiangsu. All participants provided written informed consent.

**Consent for publication**

Not applicable.

**Acknowledgements**

Our deepest gratitude to all the study participants and departments at Danyang People's Government and Danyang Lianhu Community Service Center in Jiangsu.

**Funding**

This work was supported by the National Natural Science Foundation of China [grant numbers F201901] for a study on Establishment of an early warning and individual management platform for osteoporosis fracture and sarcopenia in postmenopausal women. And supported by the National Natural Science Foundation of China [grant numbers 81771953] for a study on the mechanism of NK cells inhibiting distant metastasis induced by microwave ablation for primary breast cancer.

**Contributor Information**

Han Wu, Email: 17512595504@163.com

Yufan Zhang, Email: 1289765126@qq.com

Wenbin Zhou, Email: 13814162016@163.com

Guolong Zhang, Email: zhangguolong8251@163.com

Jindi Wang, Email: 13775504228@163.com

Jingjing Xu, Email: dsnxjj@njmu.edu.cn

Tao Yang, Email: yangt@njmu.edu.cn

Jing Dai, Email: ujsdai@163.com

Wei He, Email: hewei1007@126.com

**References**

1. Tuominen JT, Impivaara O, Puukka P, Ronnemaa T: *Bone mineral density in patients with type 1 and type 2 diabetes*. *Diabetes care* 1999, **22**(7):1196-1200.
2. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG: **Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology.** *Journal of endocrinological investigation* 2000, 23(5):295-303.

3. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, Serrano Pardo MD, Garcia-Cervigон AG: **Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study.** *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2000, 11(5):455-459.

4. Lopez-Ibarra PJ, Pastor MM, Escobar-Jimenez F, Pardo MD, Gonzalez AG, Luna JD, Requena ME, Diosdado MA: **Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus.** *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists* 2001, 7(5):346-351.

5. Isaia G, Bodrato L, Carlevatto V, Mussetta M, Salaman G, Molinatt GM: **Osteoporosis in type II diabetes.** *Acta diabetologica latina* 1987, 24(4):305-310.

6. Wakasugi M, Wakao R, Tawata M, Gan N, Koizumi K, Onaya T: **Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus.** *Bone* 1993, 14(1):29-33.

7. Barrett-Connor E, Holbrook TL: **Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus.** *Jama* 1992, 268(23):3333-3337.

8. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. *BMJ (Clinical research ed)* 2010, 340:b5463.

9. Janghorbani M, Van Dam RM, Willett WC, Hu FB: **Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.** *American journal of epidemiology* 2007, 166(5):495-505.

10. Shah VN, Shah CS, Snell-Bergeon JK: **Type 1 diabetes and risk of fracture: meta-analysis and review of the literature.** *Diabetic medicine : a journal of the British Diabetic Association* 2015, 32(9):1134-1142.

11. Fan Y, Wei F, Lang Y, Liu Y: **Diabetes mellitus and risk of hip fractures: a meta-analysis.** *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2016, 27(1):219-228.

12. Dytfeld J, Michalak M: **Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies.** *Aging clinical and experimental research* 2017, 29(2):301-309.

13. Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F: **Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies.** *European journal of epidemiology* 2012, 27(5):319-332.

14. Wang J, Yan DD, Hou XH, Bao YQ, Hu C, Zhang ZL, Jia WP: **Association of bone turnover markers with glucose metabolism in Chinese population.** *Acta pharmacologica Sinica* 2017, 38(12):1611-1617.
15. Purnamasari D, Puspitasari MD, Setiyohadi B, Nugroho P, Isbagio H: Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study. *BMC endocrine disorders* 2017, **17**(1):72.

16. Starup-Linde J, Vestergaard P: Biochemical bone turnover markers in diabetes mellitus - A systematic review. *Bone* 2016, **82**:69-78.

17. Greenblatt MB, Tsai JN, Wein MN: Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. *Clinical chemistry* 2017, **63**(2):464-474.

18. Eastell R, Szulc P: Use of bone turnover markers in postmenopausal osteoporosis. *The lancet Diabetes & endocrinology* 2017, **5**(11):908-923.

19. Curtis EM, Moon RJ, Harvey NC, Cooper C: The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. *Bone* 2017, **104**:29-38.

20. Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. *Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2007, **18**(4):427-444.

21. Schwartz AV: Diabetes Mellitus: Does it Affect Bone? *Calcified tissue international* 2003, **73**(6):515-519.

22. Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M: Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. *Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2009, **20**(6):923-933.

23. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL: Mechanisms of diabetes mellitus-induced bone fragility. *Nature reviews Endocrinology* 2017, **13**(4):208-219.

24. Ivers RQ, Cummimg RG, Mitchell P, Peduto AJ: Diabetes and risk of fracture: The Blue Mountains Eye Study. *Diabetes care* 2001, **24**(7):1198-1203.

25. Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castano-Betancourt MC, Estrada K, Stolk L, Oei EH, van Meurs JB, Janssen JA et al: High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. *Diabetes care* 2013, **36**(6):1619-1628.

26. Hussein RM: Biochemical relationships between bone turnover markers and blood glucose in patients with type 2 diabetes mellitus. *Diabetes & metabolic syndrome* 2017, **11** Suppl 1:S369-s372.

27. Furst JR, Bandeira LC, Fan WW, Agarwal S, Nishiyama KK, McMahon DJ, Dworakowski E, Jiang H, Silverberg SJ, Rubin MR: Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. *The Journal of clinical endocrinology and metabolism* 2016, **101**(6):2502-2510.

28. Reyes-Garcia R, Rozas-Moreno P, Lopez-Gallardo G, Garcia-Martin A, Varsavsky M, Aviles-Perez MD, Munoz-Torres M: Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. *Acta diabetologica* 2013, **50**(1):47-52.
29. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP: Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001, 28(2):195-201.

30. Sanguineti R, Storable D, Monacelli F, Federici A, Odeti P: Pentosidine effects on human osteoblasts in vitro. Annals of the New York Academy of Sciences 2008, 1126:166-172.

31. McCarthy AD, Uemura T, Etcheverry SB, Cortizo AM: Advanced glycation endproducts interfere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. The international journal of biochemistry & cell biology 2004, 36(5):840-848.

32. Horowitz MC, Xi Y, Wilson K, Kacena MA: Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine & growth factor reviews 2001, 12(1):9-18.

33. Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, Abboud-Werner SL: High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 2008, 42(6):1122-1130.

34. Heilmeier U, Cheng K, Pasco C, Parrish R, Nirody J, Patsch JM, Zhang CA, Joseph GB, Burghardt AJ, Schwartz AV et al: Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016, 27(9):2791-2802.

35. Yu EW, Putman MS, Derrico N, Abrishamanian-Garcia G, Finkelstein JS, Bouxsein ML: Defects in cortical microarchitecture among African-American women with type 2 diabetes. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2015, 26(2):673-679.

Figures
Figure 1

Lower bone turnover in postmenopausal women with T2DM compared to N-DM. Individuals with T2DM had lower levels of P1NP (left panel) and CTX (right panel) than N-DM controls.
Figure 1

Lower bone turnover in postmenopausal women with T2DM compared to N-DM. Individuals with T2DM had lower levels of P1NP (left panel) and CTX (right panel) than N-DM controls.